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Abstract
 
Using a tumor model of spontaneously arising insulinomas expressing a defined tumor-associated
antigen, we investigated whether tumor growth promotes cross-presentation and tolerance of
tumor-specific T cells. We found that an advanced tumor burden enhanced cross-presentation
of tumor-associated antigens to high avidity tumor-specific T cells, inducing T cell proliferation
and limited effector function in vivo. However, contrary to other models, tumor-specific T cells
were not tolerized despite a high tumor burden. In fact, in tumor-bearing mice, persistence and
responsiveness of adoptively transferred tumor-specific T cells were enhanced. Accordingly, a
potent T cell–mediated antitumor response could be elicited by intravenous administration of
tumor-derived peptide and agonistic anti-CD40 antibody or viral immunization and reimmuni-
zation. Thus, in this model, tumor growth promotes activation of high avidity tumor-specific T
cells instead of tolerance. Therefore, the host remains responsive to T cell immunotherapy.
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Introduction
 
The identification of tumor-associated antigens (TAAs)
 
*
 
has lead to the development of therapeutic strategies aimed
at activating host T cells to generate antitumor immune re-
sponses (1–3). Successful T cell immunotherapy depends
on the presence of functional T cells specific for TAAs.
Tumor-specific peripheral T cells in tumor-bearing hosts
appear to have different fates, depending on the particular
tumor model. A large number of mouse models and human
studies have reported that tumor-specific T cells become
tolerized in tumor-bearing hosts (4–15).
Tumor-induced tolerance induction may occur by a va-
riety of mechanisms, such as clonal deletion or anergy (16).
The induction of tolerance may occur after recognition of
TAAs directly on tumor cells. For example, a lack of co-
stimulatory molecules on tumor cells may render cognate T
cells unable to respond to the TAAs (17). In the case of T
cell tolerance to tumors located in tissues not normally sur-
veyed by T cells, tolerance may be induced by cross-pre-
sentation of TAAs, where tumor-derived peptides are
presented to T cells in the local draining LN by bone mar-
row–derived APCs (18, 19).
Although the factors influencing cross-presentation have
yet to be fully defined, there is evidence that ligands present
at a high concentration and those released by cellular de-
struction are most efficiently cross-presented (12, 20–23).
Cross-presentation of self-antigen can mediate T cell toler-
ance in transgenic models (24, 25). Thus, in the case of a
high tumor burden, where there are large numbers of tumor
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cells and spontaneous tumor cell death, cross-presentation of
TAAs may lead to tolerance of tumor-specific T cells.
To investigate whether tumor growth enhances cross-
presentation of TAAs and tolerance of tumor-specific T
cells, we used a model of naturally arising pancreatic can-
cer. RIP-Tag2 transgenic mice express the SV40 large T
antigen (Tag) under the control of the rat insulin promoter
(RIP; reference 26). Expression of Tag in pancreatic islet 
 
 
 
cells contributes to 
 
 
 
 cell hyperplasia and development of
solid, vascularized insulinomas at 10–12 wk of age, largely
due to Tag-mediated inactivation of the Rb and p53 tumor
suppressors (27, 28). Insulin secretion by these metaboli-
cally active tumor cells leads to progressive hypoglycemia,
and untreated mice generally succumb to the insulinomas
between 3–4 mo of age. Expression of Tag in this trans-
genic line also occurs during early embryogenesis and in
the thymus, and thus RIP-Tag2 mice are immunologically
tolerant to Tag (29, 30). To introduce a defined TAA, we
generated a double transgenic model by breeding RIP-Tag2
mice with RIP-GP mice which express a glycoprotein
from the lymphocytic choriomeningitis virus (LCMV-GP)
also in pancreatic islet 
 
 
 
 cells (31, 32). For some experi-
ments, we then crossed RIP(GP 
 
 
 
 Tag2) double trans-
genic mice to the P14 TCR transgenic line, where TCR
transgenic T cells express V
 
 
 
2 and V
 
 
 
8.1 chains that rec-
ognize the GP33 peptide from LCMV-GP in the context
of H-2D
 
b
 
 (33). Thus, the generation of P14/RIP(GP 
 
 
 
Tag2) triple transgenic mice provided a model to directly
examine the fate of endogenous tumor-specific T cells in
the presence of advanced spontaneously arising tumors ex-
pressing a defined TAA.
We first investigated whether tumor-specific T cells be-
came antigen-experienced in our model. We found that T
cell activation markers were upregulated on GP-specific T
cells in a manner dependent on presentation of TAAs by
bone marrow–derived cells. Studies using P14/RIP(GP 
 
 
 
Tag2) triple transgenic mice demonstrated that tumor
growth correlated with enhanced activation of tumor-spe-
cific T cells. We then determined whether recognition of
TAA resulted in tolerance of tumor-specific T cells and as-
sessed the effectiveness of T cell immunotherapeutic strate-
gies in this model.
 
Materials and Methods
 
Mice and Tumor Monitoring.
 
C57Bl/6 mice (H-2
 
b
 
) were pur-
chased from The Jackson Laboratory. RIP-Tag2 (originally de-
scribed as RIP1-Tag2; reference 26), RIP-GP (31), and P14
TCR (33) transgenic lines were interbred to yield RIP(GP 
 
 
 
Tag2), P14/RIP-GP, P14/RIP-Tag2 double transgenic, and
P14/RIP(GP 
 
  
 
Tag2) triple transgenic mice. P14/bm13 mice
were generated as described previously (34). Genotyping for the
P14 TCR transgene was performed by flow cytometric analysis
using anti-V
 
 
 
2 Ab (BD PharMingen). Genotyping for the RIP-
Tag2 and RIP-GP transgenes was performed by PCR as de-
scribed previously (32). Tumor progression was monitored by
blood glucose measurements once every week from 8 wk of age
onwards, and then 2–3 times per week after immunization. All
experiments were performed using mice with blood glucose lev-
els at or below 5 mM, at which time they have solid tumors (26).
The experimental endpoint occurred when blood glucose
reached 2 mM. Blood glucose levels were measured using Chem-
strips (Roche Laboratories) and Accu-Chek III glucometers
(Boehringer Mannheim).
 
Flow Cytometric Analyses.
 
Pancreatic draining LNs (PDLNs),
pooled nondraining peripheral lymph nodes (inguinal, axillary,
and cervical), and spleens were harvested and single cell suspen-
sions prepared. Lymphocytes were stained with antibodies recog-
nizing V
 
 
 
2, V
 
 
 
8.1/V
 
 
 
8.2, CD8
 
 
 
, CD44, CD69 (BD PharMin-
gen), and detection of biotin-conjugated antibodies performed
using streptavidin-conjugated red-670 (GIBCO BRL). For tet-
ramer staining, spleen cells were incubated with CD8
 
 
 
-FITC
and H-2D
 
b
 
/GP33-PE tetramers for 1 h on ice, at the indicated
dilution factors, and then washed three times. Tetramers were
provided by the tetramer core facility, National Institute of Al-
lergy and Infectious Diseases, National Institutes of Health.
Stained cells were fixed in 2% paraformaldehyde/PBS. Live
events were collected based on forward and side scatter profiles
on a FACScan™ flow cytometer (Becton Dickinson) and ana-
lyzed using CELLQuest™ software (Becton Dickinson).
 
Bone Marrow Chimeras.
 
P14 and P14/bm13 donor mice were
injected with CD4 (YTS191) and CD8 (YTS169) depleting anti-
bodies intravenously 3 d and 1 d before bone marrow transfer.
10
 
7
 
 bone marrow cells were transferred intravenously into irradi-
ated (9 Grays) sex-matched recipients, and recipients were killed
for analysis 6–13 wk after reconstitution.
 
Adoptive Transfer of P14 TCR Transgenic Cells.
 
Single cell sus-
pensions were prepared from spleens of P14 TCR transgenic
mice, and CD8
 
 
 
 T cells were purified using anti-CD8
 
 
 
–coated
beads (Miltenyi Biotech) and a magnetic activated cell sorter
(Miltenyi Biotech). For adoptive transfer of unlabeled cells, 5 
 
 
 
10
 
6
 
 P14 T cells were transferred intravenously into unirradiated
hosts, and hosts were killed for analysis 1, 2.5, and 6 wk after
transfer. For adoptive transfer of CFSE-labeled cells, the purified
cells were then labeled with CFSE (5-[and-6]-carboxyfluorescein
diacetate, succinimidyl ester); after washing once in serum-free
RPMI 1640 (GIBCO BRL), cells were resuspended in serum-free
media at 10
 
7
 
 cells per 200 
 
 
 
l containing 5 
 
 
 
M CFSE (Molecular
Probes). After incubation for 10 min at 37
 
 
 
C in an atmosphere
containing 5% CO
 
2
 
, cells were washed in RPMI 1640 containing
10% FCS (Sigma-Aldrich) and prepared for adoptive transfer.
5–10 
 
 
 
 10
 
6
 
 CD8-purified, CFSE-labeled cells were transferred in-
travenously into nonirradiated recipients, and 72 h later, organs
were harvested and stained for flow cytometric analysis.
 
Proliferation Assays.
 
P14 TCR transgenic responder LN cells
were cultured with an equivalent number of C57Bl/6 spleen cells
and 10
 
 
 
6
 
 M GP33 peptide (KAVYNFATM) or nonstimulatory
AV peptide (SGPSNTPPEI; reference 35). To assay PDLN cells,
5 
 
 
 
 10
 
4
 
 responders per well were cultured in round-bottomed
96-well plates. To assay pooled nondraining LN (NDLN) cells,
10
 
5
 
 responders per well were cultured in flat-bottomed 96-well
plates. After 48 h, cultures were pulsed with 1 
 
 
 
Ci/well [
 
3
 
H]thy-
midine (NEN Dupont) overnight and harvested onto glass fiber
filters. [
 
3
 
H]thymidine incorporation was measured using a scintil-
lation counter (Top-count; Canberra Packard).
 
CTL Assays.
 
Mice were immunized with 2,000 PFU LCMV
Armstrong intravenously. 8 d later, single cell suspensions of
PDLN cells, NDLN cells, and splenocytes were prepared as ef-
fectors. Effectors from NDLNs or spleens were plated at 6 
 
 
 
 10
 
5
 
cells per well, while PDLN cells were plated at 3 
 
 
 
 10
 
5
 
 cells per
well (due to limited cell numbers available from draining LNs)
and 6 threefold serial dilutions performed. EL-4 target cells were 
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prepared by incubation with 500 
 
 
 
Ci/ml 
 
51
 
Cr (NEN Dupont)
and 10
 
 
 
6
 
 M MB6 (KAVVNIATM) or GP33 or nonstimulatory
peptide AV (described above) for 2 h at 37
 
 
 
C. Targets were
washed three times and plated at 10
 
4
 
 cells per well with NDLN
or spleen effectors, and at 5,000 cells per well with PDLN effec-
tors in 96-well round-bottomed plates. After spinning at 1,000
rpm for 30 s, plates were incubated for 5 h at 37
 
 
 
C, and then 70
 
 
 
l of supernatant was counted for 60 s using a Wallac Wizard 
 
 
 
counter (Perkin Elmer). Maximal release was induced by adding
1 M HCl to targets. Percentage of specific lysis was calculated as
(cpm sample release 
 
 
 
 cpm spontaneous release)/(cpm maximal
release 
 
  
 
cpm spontaneous release) 
 
 
 
 100.
 
Immunotherapeutic Strategies.
 
For peptide and antibody treat-
ment, mice were treated with 5 
 
 
 
g of GP33 peptide in HBSS in-
travenously followed 2 d later with 100 
 
 
 
g of agonistic anti-
CD40 mAb (FGK45; purified rat anti–mouse) (36) intravenously
or 100 
 
 
 
g of rat polyclonal 
 
 
 
-globulin isotype-matched control
(Bio/Can Scientific). For virus immunization, mice were treated
with 2,000 PFU of LCMV Armstrong intravenously (provided
by R.M. Zinkernagel, Institute for Experimental Immunology,
Zürich, Switzerland), or 10
 
6
 
 PFU of vacc-G2 intravenously (37)
(provided by David Bishop, Oxford University, Oxford, UK), or
2,000 PFU of LCMV Armstrong intravenously followed by 10
 
6
 
PFU of vacc-G2 intravenously upon relapse of hypoglycemia.
Blood glucose levels were monitored as described above.
 
Immunohistochemistry.
 
Freshly removed pancreata were im-
mersed in O.C.T. and snap frozen in liquid nitrogen. For the
staining of cell differentiation markers, frozen tissue sections of
5-
 
 
 
m thickness were cut in a cryostat, placed on siliconized glass
slides, air dried, fixed in acetone for 10 min, and stored at –70
 
 
 
C.
Rehydrated tissue sections were incubated with primary rat mAbs
against MHC class I (H-2K
 
bkds
 
, M1/42) and CD8 (YTS 169).
Primary antibodies were revealed by sequential incubation with
goat antibodies against rat Igs, followed by alkaline phosphatase
labeled donkey antibodies against goat Igs (Jackson ImmunoRe-
search Laboratories). Dilutions of anti–Ig reagents were made in
Tris buffered saline (TBS) containing 5% normal mouse serum.
Alkaline phosphatase was visualized using naphthol AS-BI phos-
phate and new fuchsin as substrate, yielding a red color reaction
product. Endogenous alkaline phosphatase was blocked by le-
vamisole. Color reactions were performed at RT for 15 min with
reagents from Sigma-Aldrich. Sections were counterstained with
hemalum and coverslips mounted with glycerol and gelatin.
 
Results
 
Hypoglycemia Correlates with an Increased Tumor Burden in
RIP-Tag2 Mice.
 
In the RIP-Tag2 model, an increase in
islet cell mass correlates with an increase in insulin produc-
tion and a corresponding decrease in blood glucose levels.
Animals were considered to have a significant tumor bur-
den when blood glucose reach 5 mM. To quantitate the
increase in islet cell mass, histological sections of pancreata
from hypoglycemic RIP-Tag2 mice were compared with
age-matched transgene-negative mice (Table I). Measure-
ments of islets from random sections demonstrated a signif-
icant increase in the diameter of the islets in hypoglycemic
RIP-Tag2 pancreata.
 
P14 T Cells Have High Avidity for LCMV-GP33.
 
The
prevailing belief is that tolerance induction generally occurs
to self-antigen–specific T cells that are high avidity (2, 38–
41). Therefore, we wanted to determine whether the P14
transgenic tumor-specific T cells in our model represent a
low or high avidity population. Using H-D
 
b
 
/GP33 tetra-
mers, we measured the mean fluorescence intensity of
LCMV-specific T cells stained with different concentra-
tions of tetramer, which reflects the relative TCR avidity
(42, 43). A comparison of the curves for CD8
 
 
 
 T cells
from P14 TCR transgenic mice versus the endogenous,
LCMV-GP33-specific repertoire in nonTCR transgenic
mice revealed that the P14 TCR represents a receptor with
high avidity for LCMV-GP33. Surprisingly, the avidity is
slightly higher than the endogenous C57Bl/6 repertoire
expanded by LCMV (Fig. 1).
 
Enhanced Upregulation of CD44 on Tumor-specific T Cells in
Tumor-bearing Mice.
 
To determine whether tumor growth
leads to increased stimulation of tumor-specific T cells, ac-
tivation markers on P14 T cells were examined in a variety
of transgenic mice. CD44 expression levels on P14 T cells
from the PDLNs of P14/RIP(GP 
 
 
 
 Tag2) triple transgenic
mice with blood glucose levels 
 
 
 
5 mM were compared
with T cells from P14/RIP-GP mice. CD44 was upregu-
lated on P14 T cells in the PDLNs of tumor-free P14/RIP-
GP mice compared with control P14 or P14/RIP-Tag2
mice (Fig. 2 A and B). In tumor-bearing P14/RIP(GP 
 
 
 
Tag2) triple transgenic mice, CD44 expression on P14 T
cells in the PDLNs was further upregulated compared with
P14/RIP-GP mice (Fig. 2 A and B). P14 T cells isolated
from NDLNs or spleens of P14/RIP-GP or P14/RIP
(GP
 
  
 
 Tag2) mice did not show any upregulation of CD44
(Fig. 2 B), indicating that presentation of TAAs occurred
only locally and not systemically. It remains possible that
CD44 upregulation is caused by metabolic activation of the
islet cells due to Tag expression. This analysis demonstrates
that an increased tumor burden results in an increase in the
proportion of T cells that encounter antigen.
 
Table I.
 
Tumor Size in Hypoglycemic RIP-Tag2
 
 
 
 Mice
 
RIP-Tag2
 
 
 
RIP-Tag2
 
 
 
0.6 0.1
0.3 0.1
0.7 0.1
0.5 0.2
0.6 0.1
1.9 0.1
1.3 0.1
4.8
Histological sections from pancreata of naive RIP-Tag2
 
 
 
 mice taken
upon onset of blood glucose levels at or below 5 mM, or age-matched
transgene-negative controls, were stained with H&E. Diameters of islets
were measured on random sections of pancreata from 3 to 4 mice per
group using vernier gradations on a light microscope. Data are
diameters of normal islets (for transgene-negative samples) and
hyperplastic or encapsulated islets (for RIP-Tag2
 
 
 
 samples), and are
expressed in millimeters. 
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The LCMV-GP Is Cross-Presented in the PDLNs.
 
To
evaluate whether the mechanism by which tumor-specific
T cells encounter the LCMV-GP was direct recognition of
antigen presented by 
 
 
 
 cells or cross-presentation by bone
marrow–derived cells, bone marrow chimeras were gener-
ated using H-2D
 
bm13
 
 bone marrow. H-2D
 
bm13
 
 encodes an
altered H-2
 
b
 
 molecule that has three amino acid substitu-
tions in the 
 
 
 
2 peptide-binding domain (44). As a result,
the LCMV-GP33 is no longer efficiently presented by
H-2D
 
bm13
 
 (34). We generated chimeras by reconstituting
RIP-GP, RIP-Tag2, and RIP(GP 
 
 
 
 Tag2) mice with
bone marrow from P14/H-2D
 
bm13
 
 (P14/bm13) mice or
control P14/H-2D
 
b
 
 (P14/b) mice with wild-type H-2D
 
b
 
molecules. Recognition of LCMV-GP by P14 transgenic
T cells was assessed by staining for activation markers. Le-
thally irradiated RIP-GP and RIP(GP 
 
  
 
Tag2) recipients
reconstituted with bone marrow cells from P14/b mice ex-
hibited upregulation of CD69 (Fig. 3) and CD44 (data not
shown) on P14 T cells specifically in the PDLNs. In con-
trast, P14 T cells from P14/bm13 
 
→
 
RIP-GP or RIP(GP 
 
 
 
Tag2) chimeras, where GP33 could not be presented by
bone marrow–derived cells, did not exhibit upregulation of
CD69 (Fig. 3) or CD44 (data not shown). P14 T cells from
control P14/b
 
→
 
RIP-Tag2 and P14/bm13
 
→
 
RIP-Tag2
chimeras did not upregulate activation markers (data not
shown), due to the lack of the LCMV-GP33 antigen.
These observations indicate that tumor-specific T cells en-
counter cognate TAAs via cross-presentation in this model.
This degree of cross-presentation was unable to induce sig-
nificant tolerance of LCMV-GP-specific T cells, either in a
single transgenic RIP-GP model or double transgenic P14/
RIP-GP model that expresses a high proportion of
LCMV-GP–specific T cells (31).
 
Spontaneous Induction of Proliferation and Effector Function of
Tumor-specific T Cells.
 
To evaluate whether the recogni-
tion of TAAs could induce proliferation of tumor-specific
T cells, CD8
 
 
 
 T cells from naive P14 single transgenic
mice were labeled with CFSE and adoptively transferred
into RIP-GP, RIP(GP 
 
 
 
 Tag2), and transgene-negative
hosts (Fig. 4 A and B). 72 h after transfer, lymphocytes
from PDLNs (Fig. 4 A), NDLNs (Fig. 4 B), and spleens
(data not shown) were isolated from the hosts and CFSE
profiles were evaluated by flow cytometric analysis. Cell
division was induced in tumor-specific T cells recovered
from PDLNs of RIP(GP 
 
 
 
 Tag2) hosts (Fig. 4 A). No di-
vision was detected in transferred T cells recovered from
NDLNs of RIP(GP 
 
 
 
 Tag2) hosts (Fig. 4 B). In contrast to
Figure 1. P14 TCR transgenic T cells have high avidity for LCMV-
GP33. Splenocytes from naive P14 transgenic mice (black symbols) and
C57Bl/6 mice 8 d after infection with 2,000 PFU LCMV Armstrong
(white symbols) were stained with anti-CD8  Ab and the indicated dilu-
tions of H-2Db/GP33 tetramer. Mean fluorescence intensities (MFI) of
CD8  T cells representative of 3–4 mice per group from two indepen-
dent experiments are shown.
Figure 2. Enhanced upregulation of CD44 on tumor-specific T cells in
the PDLNs. Lymphocytes from the PDLNs, NDLNs, and spleens of P14,
P14/RIP-GP, and tumor-bearing P14/RIP-Tag2 and P14/RIP(GP-
Tag2) mice were gated on V 2  cells, and the percentage of CD44high
was determined. (A) Representative CD44 profiles of V 2  PDLN
cells are shown from P14 (dashed line), P14/RIP-GP (thin line), and
P14/RIP(GP   Tag2) (thick line) mice. (B) Data shown are the mean
and standard error of 3–7 mice per genotype. 
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the vigorous proliferation observed in RIP(GP 
 
 
 
 Tag2)
hosts, weak proliferation of tumor-specific T cells was in-
duced in RIP-GP hosts (Fig. 4 A). Thus, the presence of a
tumor enhanced the quantity and/or quality of cross-pre-
sentation of self-antigen, resulting in enhanced proliferation
of tumor-specific T cells.
To evaluate whether recognition of TAAs resulted in the
generation of effector function in vivo, we compared the
mean age of onset of hypoglycemia (
 
 
 
5 mM blood glu-
cose). We reasoned that any delay in the onset of hypogly-
cemia observed in naive P14/RIP(GP 
 
 
 
 Tag2) mice
would reflect “spontaneous” activation of tumor-specific T
cells and generation of a cytolytic antitumor response.
RIP-Tag2, RIP(GP 
 
 
 
 Tag2), and P14/RIP-Tag2 mice all
reached a blood glucose level 
 
 
 
5 mM at a mean age of
 
 
 
10 wk (Fig. 4 C). In contrast, triple transgenic mice be-
came hypoglycemic on average at 12.4 wk of age, a statisti-
cally significant delay compared with P14/RIP-Tag2 mice
(
 
P
 
   
 
0.005). This spontaneous antitumor activity in triple
transgenic mice indicates that cross-presentation of TAAs
can generate limited effector function which can be de-
tected in the presence of a high frequency of tumor-spe-
cific T cells.
 
Tumor-specific T Cells Do Not Show Evidence of Tolerance
Induction.
 
It has been observed that cross-presentation of
self-antigens can lead to tolerance of antigen-specific T
cells (24, 25). Studies have also shown that T cell tolerance
is preceded by expansion and activation of effector function
in many models (45–47). Thus, we wanted to test whether
the increase in tumor burden lead to the induction of T cell
tolerance in our model.
To assess whether tumor-specific T cells were tolerized
by clonal deletion, PDLNs were isolated from tumor-bear-
ing P14/RIP(GP 
 
 
 
 Tag2) triple transgenic mice and con-
trol mice, and the proportion of tumor-specific T cells de-
termined by flow cytometric analysis (Fig. 5 A). We were
unable to detect a reduction of tumor-specific T cells, as
the percentage of P14 transgenic T cells in PDLNs of triple
transgenic mice was similar to P14, P14/RIP-GP, and
P14/RIP-Tag2 mice. Analyses of NDLNs and spleens also
revealed normal proportions of tumor-specific T cells.
Another mechanism of T cell tolerance is the induction
of unresponsiveness (48). T cells from the PDLNs of P14/
RIP(GP 
 
 
 
 Tag2) triple transgenic mice were assayed for
their proliferative responses to tumor-specific peptide in
vitro. Proliferative responses of PDLN T cells to GP33
peptide from 6 of 7 triple transgenic mice were similar to
controls (Fig. 5 B). In addition, GP33-induced prolifera-
tion of T cells from NDLNs and spleens of triple trans-
genic mice was normal (Fig. 5 C and data not shown,
respectively). In 1 of 7 triple transgenic mice, the prolifera-
tive response of PDLN T cells was reduced to 
 
 
 
30% of
the normal level, and was partially rescued by addition of
conA supernatant (data not shown). However, T cells from
other peripheral LNs of this particular mouse showed nor-
mal GP33-induced proliferation (data not shown). In gen-
eral, the proliferation data indicate that tumor-specific T
cells remain responsive both systemically and locally in the
regional LN.
Although these results are consistent with a lack of T cell
deletion and anergy, it remains possible that a subset of tu-
mor-specific T cells was in fact deleted or anergized, and
the production of a large number of tumor-specific T cells
by the thymus in TCR transgenic mice replenished the de-
leted repertoire or compensated for any unresponsive P14
T cells. To address this possibility, we examined the fate of
adoptively transferred P14 T cells in tumor-bearing,
nonP14 transgenic hosts over time. V
 
 
 
2
 
 
 
 CD8
 
 
 
 T cells in
Figure 3. The LCMV-GP is
cross-presented in the PDLNs.
Bone-marrow cells from P14/b
(top) or P14/bm13 (bottom) mice
were transferred into lethally irradi-
ated RIP-GP and RIP(GP   Tag2)
recipients. Representative CD69
profiles (gated on V 2 CD8  cells)
are shown for PDLNs and NDLNs
from recipients 6 wk after transfer.
Results are representative of 2–9
mice per group from three indepen-
dent experiments. 
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PDLNs and NDLNs were enumerated at 1, 2.5, and 6 wk
after transfer of 5 
 
 
 
 10
 
6
 
 P14 T cells into RIP(GP
 
  
 
 Tag2)
and control hosts (nontransgenic, RIP-GP, and RIP-
Tag2). Interestingly, the number of P14 T cells recovered
from the PDLNs of RIP(GP 
 
 
 
 Tag2) hosts was increased
compared with control hosts at all time points (Fig. 6 A).
The highest number of P14 T cells was observed in the
PDLNs after 1 wk and was maintained at a fairly constant
cell number at 2.5 and 6 wk. This tumor-dependent ex-
pansion of tumor-specific T cells was specific to the
PDLNs, as the number of P14 T cells recovered from
NDLNs was similar in all genotypes at all time points (data
not shown). Thus, in this situation where there were a re-
stricted number of tumor-specific T cells, we did not de-
tect deletion and in fact observed enhanced numbers of
these T cells in PDLNs compared with antigen-negative
and/or tumor-free mice at 6 wk after adoptive transfer. In
addition, a comparison between pancreatic sections from 1
and 6 wk time points revealed an increase in CD8
 
 
 
 T cell
islet infiltration in RIP(GP 
 
 
 
 Tag2) hosts over time (Fig. 6
B). Thus, the approximate twofold decline of total V
 
 
 
2
 
 
 
CD8
 
 
 
 T cells in the PDLNs from 1 to 6 wk correlated
with an approximate twofold increase in cells in the pan-
creatic islets. Together these data demonstrate that expan-
sion of P14 T cells was seen only in the presence of the tu-
mor and only in the PDLNs. There was no evidence for
deletion of tumor-specific T cells, but rather, a clear migra-
tion to the tumor in the pancreas.
Using the adoptive transfer system, we also assessed
whether tumor-specific T cells remained functional at 3
and 6 wk time points. We have previously identified a
novel peptide, MB6, which is recognized only by acti-
vated P14 TCR transgenic T cells, and not CTLs derived
from LCMV-infected C57Bl/6 mice (49). After adoptive
transfer of P14 T cells, hosts were challenged with
LCMV, and 8 d later, PDLN cells, NDLN cells, and sple-
Figure 4. Spontaneous induction of proliferation
and effector function of tumor-specific T cells. (A and
B) CFSE-labeled, naive P14 transgenic T cells were
adoptively transferred into nontransgenic, RIP-GP, or
tumor-bearing RIP(GP   Tag2) hosts. 72 h later, lym-
phocytes from PDLNs (A) and NDLNs (B) were gated
on V 2  lymphocytes and CFSE profiles determined.
Profiles are representative of 5–7 mice from each geno-
type, from three independent experiments. (C) The
age at which blood glucose levels dropped to or below
5 mM was recorded for RIP-Tag2, RIP(GP   Tag2),
P14/RIP-Tag2, and P14/RIP(GP   Tag2) mice. In-
dividual mouse data are shown, the horizontal bar indi-
cates the mean onset of hypoglycemia. 
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nocytes were assayed for CTL activity against the wild-
type GP33 peptide and the altered peptide ligand, MB6.
Thus, the generation of lytic activity against MB6 indi-
cates a continued presence and functionality of adoptively
transferred P14 T cells. Data in Table II show that, as ex-
pected, T cells from nontransgenic (C57Bl/6) mice with-
out adoptive transfer did not lyse MB6-coated targets after
LCMV immunization. In contrast, both local and systemic
T cells from RIP(GP 
 
 
 
 Tag2) hosts, immunized with
LCMV 6 wk after adoptive transfer of P14 T cells, were
able to lyse MB6-coated targets. This demonstrates that
functional P14 tumor-specific T cells remained in the tu-
mor-bearing mice. The lack of expansion of tumor-spe-
cific T cells we observed in PDLNs of nontransgenic hosts
relative to RIP(GP 
 
  
 
Tag2) hosts (Fig. 6 A) is consistent
with the finding that T cells from PDLNs of nontrans-
genic hosts immunized with LCMV 6 wk after adoptive
transfer did not lyse MB6-coated targets (Table II). T cells
Figure 5. No significant toler-
ance induction of tumor-specific
T cells in P14/RIP(GP   Tag2)
mice. (A) Deletion was assessed
by isolating PDLNs, NDLNs, and
spleens from P14, P14/RIP-GP,
tumor-bearing P14/RIP-Tag2,
and P14/RIP(GP   Tag2) mice.
The percentage of P14 transgenic
was determined by the percent-
age of V 2  of lymphocytes by
flow cytometric analysis. Data
shown are the mean and stan-
dard deviation of 3–7 mice per
genotype. (B and C) Anergy was
assessed by proliferation assay of
PDLN cells (B) and NDLN cells
(C). Lymph node cells were in-
cubated with C57Bl/6 spleen
cell stimulators prepulsed with
10 7 M GP33 or negative con-
trol peptide AV. Data shown are
from two mice per genotype,
and results are representative of
four experiments.
Figure 6. Persistence of adoptively transferred tumor-specific T cells in RIP(GP   Tag2)
mice. (A) Recovery of tumor-specific T cells from PDLNs was assessed 1, 2.5, and 6 wk af-
ter adoptive transfer of 5   106 P14 T cells into control and RIP(GP   Tag2) hosts. Data
from individual mice are shown, and the horizontal bar indicates the mean of each data set.
(B) The indicated mice were killed 1 and 6 wk after adoptive transfer, and pancreatic sec-
tions stained for CD8  T cells. All controls at the 1 wk time point had no infiltrating CD8 
T cells, as at the 6 wk time point. Each point represents the number of CD8  T cells in one
islet, and the horizontal bar indicates the mean value for each data set. CD8  T cells in
11–28 individual islets from 5–8 different sections were enumerated for each data set. 
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from all mice at each time point efficiently lysed GP33-
coated targets (data not shown). Similar results as de-
scribed above were observed at the 3 wk time point (data
not shown).
Thus, no deletion or anergy of high avidity tumor-spe-
cific T cells occurred in P14/RIP(GP 
 
 
 
 Tag2) triple trans-
genic mice, or upon adoptive transfer into RIP(GP 
 
 
 
Tag2) mice. In fact, local expansion of functional tumor-
specific T cells was observed upon adoptive transfer into
tumor-bearing transgenic hosts.
 
Administration of Tumor-specific Peptide and Anti-CD40
mAb Induces CTL Infiltration of Tumors, Tumor Regression,
and Prolonged Animal Lifespan.
 
To confirm that tumor-
specific T cells in P14/RIP(GP 
 
  Tag2) triple transgenic
mice could function in vivo, we attempted to elicit an anti-
tumor response in vivo. We have previously reported that
intravenous administration of GP33 peptide and agonistic
anti-CD40 mAb into P14/RIP-GP mice results in the acti-
vation of P14 T cells, insulitis, CTL-mediated pancreatic  
cell destruction, and diabetes (50). Treatment of P14/
RIP(GP   Tag2) triple transgenic mice with this same reg-
imen resulted in infiltration of CD8  T cells into insulino-
mas 5 d after peptide injection (Fig. 7 B). Infiltration was
antigen-specific, as insulinomas not expressing LCMV-GP
did not become infiltrated upon immunization (Fig. 7 A).
MHC class I expression in insulinomas of triple transgenic
mice was also markedly upregulated after peptide and anti-
CD40 mAb treatment (Fig. 7 C and D). In addition to
CTL infiltration, potent cytolytic effector function was
generated: peptide and anti-CD40 mAb treated triple trans-
genic mice were rescued from hypoglycemia, reflecting de-
struction of tumorigenic   cells (Fig. 7 E). This antitumor
activity resulted in prolonged animal lifespan, with triple
transgenic animals surviving on average 10 wk longer after
immunization compared with control mice not expressing
LCMV-GP (P   0.0005, Fig. 7 F). These results show that
any undetectable T cell deletion that may have occurred in
P14/RIP(GP   Tag2) mice was not sufficient to prevent
priming of an antitumor response.
Antitumor Activity Is Elicited in NonTCR Transgenic Mice
by Viral Immunization and Reimmunization. We have pre-
viously shown that a potent antitumor response is elicited
in RIP(GP   Tag2) double transgenic mice upon immuni-
zation with LCMV (32). Together with the data presented
in this study, this indicates that T cells are not significantly
tolerized even in nonTCR transgenic tumor-bearing mice,
with a normal endogenous repertoire of tumor-specific T
cells. To further evaluate the responsiveness of endogenous
tumor-specific T cells, we attempted to elicit antitumor ac-
tivity by immunizing RIP(GP   Tag2) mice with a re-
combinant vaccinia virus expressing the LCMV-GP (vacc-
G2) (37), which is a weaker CTL stimulus than LCMV
(51). We found that animal survival was prolonged by a
single immunization with vacc-G2, compared with immu-
nization of RIP-Tag2 mice not expressing the LCMV-GP
(P   0.006) (Fig. 8). The ability of this weaker vacc-G2
stimulus to prime tumor-specific T cells further demon-
strates that significant tumor-specific T cell tolerance did
not occur in nonTCR transgenic mice.
Although immunization of RIP(GP   Tag2) mice with
LCMV resulted in tumor regression, the antitumor re-
sponse was transient, as the tumor itself was not sufficiently
immunogenic to maintain tumor-specific CTL activity
(32). To evaluate whether tumor-specific T cells were still
functional in vivo after tumor relapse and consequently
prolonged exposure to TAAs, we attempted to boost
RIP(GP   Tag2) mice with vacc-G2 upon relapse of hy-
poglycemia. RIP(GP    Tag2) mice immunized with
LCMV followed by a vacc-G2 boost (given on average
23   2 d after primary LCMV immunization) had a statis-
tically significant prolonged lifespan, compared with the
same mice immunized with LCMV only (Fig. 8, P   
0.005). All RIP(GP   Tag2) mice succumbed to tumor re-
lapse after secondary immunization with vacc-G2, suggest-
ing that further immunizations would be required in order
to maintain antitumor activity. The ability of repetitive im-
munization to further enhance animal survival indicates
that in addition to a lack of significant T cell tolerance in
Table II. Adoptively Transferred Tumor-specific T Cells Retain Functionality in RIP(GP   Tag2) Hosts
PDLN cells Splenocytes
Recipient genotype Adoptive transfer of P14 T cells MB6 targets AV targets MB6 targets AV targets
Nontransgenic   5527
Nontransgenic   5 2 23 0
RIP (GP   Tag2)   20 2 45 2
RIP (GP   Tag2)   18 2 35 2
5   106 P14 TCR transgenic T cells were adoptively transferred into the indicated recipient mice. 6 wk after transfer, all mice were infected with
2,000 PFU LCMV intravenously. 8 d after infection, PDLN cells and splenocytes were assayed for their cytotoxic activity against EL-4 targets pulsed
with MB6 or negative control AV peptide. Data is expressed as the percentage of specific lysis at effector/target ratios of 60:1, with 104 effectors from
spleens plated per well and only 5,000 effectors from draining LNs plated per well, due to the limited number of cells available in draining LNs.
Spontaneous 51Cr release was  15%. Results are representative of data from two independent experiments.431 Nguyen et al.
naive tumor-bearing mice, tumor-specific T cells remained
responsive despite an extended exposure to TAAs in vivo.
Discussion
Tumor Growth Enhances Activation of Tumor-specific T Cells
in the Local Draining LNs. This study demonstrates that
tumor growth leads to increased detection of TAAs by tu-
mor-specific T cells. The impact of an increased tumor
load is evident in the upregulation of CD44 and the induc-
tion of proliferation of CFSE-labeled tumor-specific T
cells. In P14/RIP-GP mice,  25% of P14 T cells upregu-
lated CD44 expression (Fig. 2), and adoptive transfer of
P14 T cells into RIP-GP mice resulted in limited prolifera-
tion (Fig.4 A). In contrast, in P14/RIP(GP   Tag2) mice
with an advanced tumor burden, an increased percentage
of P14 T cells upregulated CD44 ( 50%), and adoptive
transfer of P14 T cells into RIP(GP   Tag2) mice resulted
in vigorous proliferation. Thus, the effect of cross-presenta-
tion was enhanced with tumor growth.
Figure 7. Active immunotherapy induces efficient antitumor CTLs in P14/RIP(GP   Tag2) mice. (A–F) Administration of tumor-specific peptide
and anti-CD40 mAb induces antitumor activity. (A–D) Tumor-bearing P14/RIP(GP   Tag2) and P14/RIP-Tag2 mice were treated with 5  g of
GP33 peptide intravenously followed 2 d later with 100  g of anti-CD40 mAb intravenously. Pancreata were harvested 5 d after peptide injection and
sections were stained for CD8 (A and B) and MHC class I (C and D). Arrows indicate the location of tumors. Original magnification: 100 . (E) Repre-
sentative blood glucose levels after peptide injection are shown. (F) P14/RIP(GP   Tag2) and P14/RIP-Tag2 mice were treated with 5  g of GP33
peptide intravenously followed 2 d later with 100  g of anti-CD40 mAb intravenously or 100  g of isotype-matched control Ab intravenously. Mean
and standard error of survival after peptide injection are shown of 3–7 mice per group.432 Tumor Growth Favors T Cell Immunity versus Tolerance
T Cell Tolerance, Activation, and Immunosurveillance.
Numerous studies have investigated whether the presence
of a tumor leads to tolerance of tumor-specific T cells. Tu-
mor-induced T cell tolerance has been reported to occur
by different mechanisms in various situations, in both
mouse models (4, 7, 11, 15, 52) and human studies (5,
8–10, 13). However, studies have also shown that tumor-
specific T cells may become activated in the presence of
a tumor, or they may remain ignorant of TAAs and con-
sequently have the potential to be activated by immuno-
therapy (15, 53–59). We have addressed the issue of tu-
mor-induced T cell tolerance in a model of endogenous
tumors and defined TAAs. We have demonstrated that tu-
mor-specific T cells encounter cognate antigen in tumor-
bearing hosts, but did not find evidence for tolerance in-
duction. In tumor-bearing P14/RIP(GP   Tag2) animals,
the percentage of endogenous transgenic tumor-specific T
cells and their proliferative capacity remains similar to tu-
mor-free animals (Fig. 5). Cross-presented tumor antigens
were able to promote the expansion of adoptively trans-
ferred high avidity tumor-specific T cells into tumor-bear-
ing mice (Fig. 6 A and B). There was no evidence for tol-
erance since these T cells were present and remained
functional to subsequent virus challenge (Table II). Previ-
ous studies have shown that virus immunization was unable
to break LCMV-GP-induced tolerance of nondeleted T
cells (46, 60). Therefore, the detection of P14-specific cy-
tolytic T cells after LCMV challenge reflects the presence
of functional P14 transgenic T cells, rather than the activa-
tion of tolerized cells or “breaking” tolerance. Thus, evi-
dence from our studies demonstrate that high avidity tu-
mor-specific T cells are not tolerized in vivo.
Many factors may influence the induction of T cell im-
munity versus tolerance. Generally, T cell tolerance is
thought to occur when T cells encounter antigen on “im-
mature” or resting APCs, while effective T cell activation is
promoted through antigen-specific interactions with acti-
vated, mature APCs (61–66). An important component of
APC maturation is the generation of proinflammatory sig-
nals. Our data support a scenario where the high degree of
cell death inherent in rapidly proliferating tumors, together
with an increase in total mass, confers a proinflammatory
environment, sufficient to subvert the induction of toler-
ance and promote inflammation and immunity. It is likely
that many other factors contribute to the proinflammatory
environment associated with the tumor, such as other cy-
tokines including TNF- .
Why then does T cell tolerance occur in some models?
Although cross-presentation of tissue-specific antigens has
been shown to lead to tolerance, these models expressed a
defined self-antigen in tissues where inflammatory signals
are not normally present (24, 25). Many studies that have
observed T cell tolerance to tumors involve haematological
or metastasizing tumors, intravenously administered tumor
cells or examine tumor infiltrating lymphocytes (5, 6, 8, 9,
11, 13, 15, 67). In these cases, direct presentation may oc-
cur and induce tolerance, or perhaps the tumor is per-
ceived as noninvasive and therefore does not promote in-
flammatory signals and “immunogenic” cross-presentation
on activated APCs.
In contrast to models of transplanted tumors, the RIP-
Tag2 model of spontaneously arising tumors of endoge-
nous origin is well suited for examining issues concern-
ing natural tumor immunosurveillance (68, 69). In our
model, despite the overwhelmingly tumor-specific T cell
repertoire in P14/RIP(GP   Tag2) animals and evidence
for their activation by TAAs, immunosurveillance is inef-
ficient in preventing tumor development. This is likely
due to the limited degree of cross-presentation in the re-
gional LNs, which would result in insufficient numbers of
activated tumor-specific T cells to protect the host from
tumor growth.
Induction of Antitumor Immunity. Recent developments
in immunotherapeutic strategies include attempts to activate
endogenous tumor-specific T cells by transfusion of mature
dendritic cells presenting tumor-derived peptides (70–72).
Maturation of dendritic cells results in their ability to effi-
ciently activate naive CTLs, by virtue of the upregulation of
a range of costimulatory, adhesion, and cytokine molecules
(73). Among the dendritic cell maturation signals that have
been identified is ligation of CD40 by its ligand, CD154
(74–77). We show here that intravenous treatment of P14/
RIP(GP    Tag2) mice bearing advanced tumors with
GP33 tumor-derived peptide and agonistic anti-CD40 mAb
elicits a potent antitumor CTL response that results in
greatly enhanced animal lifespan. This data, together with
other studies that demonstrate antitumor immunity after in
vivo ligation of CD40 (78–85), indicate that CD40-based
therapeutic strategies present a practical alternative to strate-
gies that rely on ex vivo generation of dendritic cells manip-
ulated to express TAAs. The results presented here showed
that all tumor-bearing mice immunized with GP33 and
anti-CD40 mAb or viruses experienced tumor relapse. This
indicates that therapeutic immunization with self-antigens
must be done in a strong and repetitive manner in order to
effectively control tumor growth.
Figure 8. Viral immunization and reimmunization of RIP(GP  
Tag2) mice elicits antitumor activity. RIP-Tag2 and RIP(GP   Tag2)
tumor-bearing mice were immunized with 2,000 PFU LCMV intrave-
nously, or 106 PFU vacc-G2 intravenously, or were boosted with vacc-G2
upon tumor relapse after primary LCMV immunization. Mean and stan-
dard error of survival after initial immunization are shown of 5–14 mice
per group.433 Nguyen et al.
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